Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Viking Therapeutics, Inc. (VKTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.7600+0.1800 (+5.03%)
At close: 04:00PM EDT
3.7500 -0.01 (-0.27%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.5800
Open3.5800
Bid3.6800 x 2200
Ask3.7500 x 1000
Day's Range3.5800 - 3.7700
52 Week Range2.0200 - 7.2000
Volume505,956
Avg. Volume1,144,232
Market Cap294.163M
Beta (5Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Viking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022

    Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the BTIG Biotechnology Conference 2022. The conference will take place August 8-9, 2022.

  • PR Newswire

    Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2022, and provided an update on its clinical pipeline and other corporate developments.

  • PR Newswire

    Viking Therapeutics to Report Financial Results for Second Quarter 2022 on July 27, 2022

    Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2022, after the market close on Wednesday, July 27, 2022.

Advertisement
Advertisement